- Home
- DBD vs GENB Comparison
DBD vs GENB Comparison
Compare DBD & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DBD | GENB |
|---|---|---|
| Founded | 1859 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2023 | 2026 |
Fundamental Metrics
Financial Performance| Metric | DBD | GENB |
|---|---|---|
| Price | $66.65 | $15.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $90.00 | $23.20 |
| AVG Volume (30 Days) | 245.5K | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 677.27 | N/A |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $3,805,700,000.00 | N/A |
| Revenue This Year | $3.56 | N/A |
| Revenue Next Year | $3.25 | $16.58 |
| P/E Ratio | $116.97 | ★ N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $54.48 | $11.00 |
| 52 Week High | $92.09 | $22.67 |
Technical Indicators
Market Signals| Indicator | DBD | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 33.74 | 50.90 |
| Support Level | $63.70 | $12.05 |
| Resistance Level | $69.26 | $17.46 |
| Average True Range (ATR) | 2.12 | 1.69 |
| MACD | 0.13 | -0.13 |
| Stochastic Oscillator | 11.69 | 15.02 |
Price Performance
Historical ComparisonAbout DBD Diebold Nixdorf Incorporated
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment.
About GENB Generate Biomedicines Inc. Common Stock
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.